Amyloid beta, a key peptide in Alzheimer’s disease, forms plaques in the brain contributing to neurodegeneration. FDA-approved drugs like lecanemab and donanemab target amyloid aggregates, yet their limited efficacy hints at other disease mechanisms. Proteomic studies of Alzheimer’s brains reveal proteins, such as midkine, highly associated with amyloid beta, suggesting unexplored roles in disease progression.
In a recent study published in Nature Structural & Molecular Biology, researchers from St. Jude Children’s Research Hospital shed light on midkine’s potential in Alzheimer’s. Midkine, known for its diverse biological functions, emerges as a significant player in preventing amyloid beta aggregation and plaque formation, presenting a novel avenue for therapeutic exploration.
Experiments using thioflavin T, circular dichroism, electron microscopy, and nuclear magnetic resonance illustrate midkine’s interference with amyloid beta aggregation, particularly targeting elongation and secondary nucleation pathways. By employing kinetic data fitting, researchers highlight midkine’s preference for inhibiting secondary nucleation, thereby impeding amyloid fibril growth and plaque formation.
Genetic knockout studies of theMdkgene encoding midkine resulted in increased amyloid formation and microglial activation in mouse models. Mass spectrometry profiling revealed elevated amyloid beta levels and correlated proteins in these models, emphasizing midkine’s role in modulating amyloid dynamics and associated neuroinflammatory responses.
Beyond its anti-aggregation properties, midkine serves as a growth factor promoting neuronal growth and survival. Its interactions with receptors like LRP1, linked to Alzheimer’s risk factors, further underscore its multifaceted influence in neurodegenerative processes. Understanding the atomic-level interactions between midkine and amyloid beta could pave the way for designing targeted therapeutic interventions.
The potential implications of midkine in Alzheimer’s treatment highlight the importance of further investigations to elucidate its precise mechanisms and optimize therapeutic strategies. By unraveling the intricate interplay between midkine and amyloid beta, researchers aim to develop innovative treatments that mimic midkine’s protective effects, offering new possibilities in the realm of neurological disease management.
Key Takeaways:
– Midkine protein shows promise in attenuating amyloid beta aggregation and plaque formation in Alzheimer’s disease models.
– Understanding the molecular interactions between midkine and amyloid beta could inspire the design of targeted therapeutics.
– Midkine’s multifunctional properties, including growth factor activity and receptor interactions, present new avenues for drug discovery in neurological disorders.
Tags: immunotherapy, proteomics, metabolomics, biotech
Read more on genengnews.com